Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans.

Schmajuk G, Trivedi AN, Solomon DH, Yelin E, Trupin L, Chakravarty EF, Yazdany J.

JAMA. 2011 Feb 2;305(5):480-6. doi: 10.1001/jama.2011.67.

PMID:
21285425
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Etanercept for the treatment of rheumatoid arthritis.

Lethaby A, Lopez-Olivo MA, Maxwell L, Burls A, Tugwell P, Wells GA.

Cochrane Database Syst Rev. 2013 May 31;5:CD004525. doi: 10.1002/14651858.CD004525.pub2. Review.

PMID:
23728649
[PubMed - indexed for MEDLINE]
3.

An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.

van Roon EN, van den Bemt PM, Jansen TL, Houtman NM, van de Laar MA, Brouwers JR.

Clin Ther. 2009 Aug;31(8):1737-46. doi: 10.1016/j.clinthera.2009.08.009. Review.

PMID:
19808132
[PubMed - indexed for MEDLINE]
4.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

PMID:
17049139
[PubMed - indexed for MEDLINE]
Free Article
5.

Patterns of disease-modifying antirheumatic drug use in rheumatoid arthritis patients after 2002: a systematic review.

Schmajuk G, Solomon DH, Yazdany J.

Arthritis Care Res (Hoboken). 2013 Dec;65(12):1927-35. doi: 10.1002/acr.22084. Review.

PMID:
23926092
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk